Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines
SARS-CoV-2 vaccination has been recommended for liver transplant (LT) recipients. However, our understanding of inactivated vaccine stimulation of the immune system in regulating humoral and cellular immunity among LT recipients is inadequate. Forty-six LT recipients who received two-dose inactivate...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.954177/full |
| _version_ | 1828104974476771328 |
|---|---|
| author | Binwei Duan Binwei Duan Gongming Zhang Gongming Zhang Wenjing Wang Wenjing Wang Jiming Yin Jiming Yin Mengcheng Liu Mengcheng Liu Mengcheng Liu Jing Zhang Jing Zhang Dexi Chen Dexi Chen Yabo Ouyang Yabo Ouyang Yabo Ouyang Guangming Li Guangming Li |
| author_facet | Binwei Duan Binwei Duan Gongming Zhang Gongming Zhang Wenjing Wang Wenjing Wang Jiming Yin Jiming Yin Mengcheng Liu Mengcheng Liu Mengcheng Liu Jing Zhang Jing Zhang Dexi Chen Dexi Chen Yabo Ouyang Yabo Ouyang Yabo Ouyang Guangming Li Guangming Li |
| author_sort | Binwei Duan |
| collection | DOAJ |
| description | SARS-CoV-2 vaccination has been recommended for liver transplant (LT) recipients. However, our understanding of inactivated vaccine stimulation of the immune system in regulating humoral and cellular immunity among LT recipients is inadequate. Forty-six LT recipients who received two-dose inactivated vaccines according to the national vaccination schedule were enrolled. The clinical characteristics, antibody responses, single-cell peripheral immune profiling, and plasma cytokine/chemokine/growth factor levels were recorded. Sixteen (34.78%) LT recipients with positive neutralizing antibody (nAb) were present in the Type 1 group. Fourteen and 16 LT recipients with undetected nAb were present in the Type 2 and Type 3 groups, respectively. Time from transplant and lymphocyte count were different among the three groups. The levels of anti-RBD and anti-S1S2 decreased with decreasing neutralizing inhibition rates. Compared to the Type 2 and Type 3 groups, the Type 1 group had an enhanced innate immune response. The proportions of B, DNT, and CD3+CD19+ cells were increased in the Type 1 group, whereas monocytes and CD4+ T cells were decreased. High CD19, high CD8+CD45RA+ cells, and low effector memory CD4+/naïve CD4+ cells of the T-cell populations were present in the Type 1 group. The Type 1 group had higher concentrations of plasma CXCL10, MIP-1 beta, and TNF-alpha. No severe adverse events were reported in all LT recipients. We identified the immune responses induced by inactivated vaccines among LT recipients and provided insights into the identification of immunotypes associated with the responders. |
| first_indexed | 2024-04-11T09:56:28Z |
| format | Article |
| id | doaj.art-a0d57f828c08472297b64bfac2f66852 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T09:56:28Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a0d57f828c08472297b64bfac2f668522022-12-22T04:30:36ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.954177954177Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccinesBinwei Duan0Binwei Duan1Gongming Zhang2Gongming Zhang3Wenjing Wang4Wenjing Wang5Jiming Yin6Jiming Yin7Mengcheng Liu8Mengcheng Liu9Mengcheng Liu10Jing Zhang11Jing Zhang12Dexi Chen13Dexi Chen14Yabo Ouyang15Yabo Ouyang16Yabo Ouyang17Guangming Li18Guangming Li19Department of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaClinical Center for Liver Cancer, Capital Medical University, Beijing, ChinaDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaClinical Center for Liver Cancer, Capital Medical University, Beijing, ChinaDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, Beijing, ChinaDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, Beijing, ChinaDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaClinical Center for Liver Cancer, Capital Medical University, Beijing, ChinaBeijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, Beijing, ChinaDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaClinical Center for Liver Cancer, Capital Medical University, Beijing, ChinaDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, Beijing, ChinaDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaClinical Center for Liver Cancer, Capital Medical University, Beijing, ChinaBeijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, Beijing, ChinaDepartment of General Surgery Center, Beijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaClinical Center for Liver Cancer, Capital Medical University, Beijing, ChinaSARS-CoV-2 vaccination has been recommended for liver transplant (LT) recipients. However, our understanding of inactivated vaccine stimulation of the immune system in regulating humoral and cellular immunity among LT recipients is inadequate. Forty-six LT recipients who received two-dose inactivated vaccines according to the national vaccination schedule were enrolled. The clinical characteristics, antibody responses, single-cell peripheral immune profiling, and plasma cytokine/chemokine/growth factor levels were recorded. Sixteen (34.78%) LT recipients with positive neutralizing antibody (nAb) were present in the Type 1 group. Fourteen and 16 LT recipients with undetected nAb were present in the Type 2 and Type 3 groups, respectively. Time from transplant and lymphocyte count were different among the three groups. The levels of anti-RBD and anti-S1S2 decreased with decreasing neutralizing inhibition rates. Compared to the Type 2 and Type 3 groups, the Type 1 group had an enhanced innate immune response. The proportions of B, DNT, and CD3+CD19+ cells were increased in the Type 1 group, whereas monocytes and CD4+ T cells were decreased. High CD19, high CD8+CD45RA+ cells, and low effector memory CD4+/naïve CD4+ cells of the T-cell populations were present in the Type 1 group. The Type 1 group had higher concentrations of plasma CXCL10, MIP-1 beta, and TNF-alpha. No severe adverse events were reported in all LT recipients. We identified the immune responses induced by inactivated vaccines among LT recipients and provided insights into the identification of immunotypes associated with the responders.https://www.frontiersin.org/articles/10.3389/fimmu.2022.954177/fullSARS-CoV-2 inactivated vaccinesliver transplant recipientneutralizing antibodiesCD3+ CD19+ cellCXCL10 |
| spellingShingle | Binwei Duan Binwei Duan Gongming Zhang Gongming Zhang Wenjing Wang Wenjing Wang Jiming Yin Jiming Yin Mengcheng Liu Mengcheng Liu Mengcheng Liu Jing Zhang Jing Zhang Dexi Chen Dexi Chen Yabo Ouyang Yabo Ouyang Yabo Ouyang Guangming Li Guangming Li Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines Frontiers in Immunology SARS-CoV-2 inactivated vaccines liver transplant recipient neutralizing antibodies CD3+ CD19+ cell CXCL10 |
| title | Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines |
| title_full | Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines |
| title_fullStr | Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines |
| title_full_unstemmed | Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines |
| title_short | Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines |
| title_sort | immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with sars cov 2 inactivated vaccines |
| topic | SARS-CoV-2 inactivated vaccines liver transplant recipient neutralizing antibodies CD3+ CD19+ cell CXCL10 |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.954177/full |
| work_keys_str_mv | AT binweiduan immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT binweiduan immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT gongmingzhang immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT gongmingzhang immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT wenjingwang immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT wenjingwang immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT jimingyin immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT jimingyin immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT mengchengliu immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT mengchengliu immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT mengchengliu immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT jingzhang immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT jingzhang immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT dexichen immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT dexichen immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT yaboouyang immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT yaboouyang immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT yaboouyang immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT guangmingli immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines AT guangmingli immunogenicityprofilinganddistinctimmuneresponseinlivertransplantrecipientsvaccinatedwithsarscov2inactivatedvaccines |